Goldman Sachs resumed coverage of Ideaya Biosciences (IDYA) with a Neutral rating and $25 price target The firm views 2025 as an execution year for the company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target lowered to $30 from $57 at RBC Capital
- IDEAYA Biosciences Appoints New Chief Financial Officer
- General Mills upgraded, Trade Desk downgraded: Wall Street’s top analyst calls
- Ideaya Biosciences initiated with an Overweight at Wells Fargo
- IDEAYA Biosciences Holds Annual Stockholders Meeting